AN2 Therapeutics, Inc. Increase (Decrease) in Other Current Liabilities
AN2 Therapeutics, Inc. (ANTX) reported Increase (Decrease) in Other Current Liabilities of -$453.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-11
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was $209.00K, a 39.94% decline year-over-year.
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was -$662.00K.
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was $1.05M.
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was -$534.00K, a 174.48% decline year-over-year.
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2025 was $438.00K, a 247.62% increase from fiscal 2024.
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2024 was $126.00K, a 81.08% decline from fiscal 2023.
- AN2 Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2023 was $666.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$453.00K 10-Q · filed 2026-08-11 | $593.00K derived: sum of 3 quarters · filed 2026-08-11 | $59.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$662.00K 10-Q · filed 2026-05-11 | $384.00K derived: sum of 2 quarters · filed 2026-05-11 | -$150.00K derived: sum of 3 quarters · filed 2026-05-11 | $198.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $512.00K derived: sum of 2 quarters · filed 2026-03-17 | $860.00K derived: sum of 3 quarters · filed 2026-08-11 | $438.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$534.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$186.00K derived: sum of 2 quarters · filed 2026-08-11 | -$608.00K 10-Q · filed 2025-11-12 | -$1.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $348.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$74.00K 10-Q · filed 2026-08-11 | -$558.00K derived: sum of 3 quarters · filed 2026-08-11 | $159.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$422.00K 10-Q · filed 2026-05-11 | -$906.00K derived: sum of 2 quarters · filed 2026-05-11 | -$189.00K derived: sum of 3 quarters · filed 2026-05-11 | $50.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $233.00K derived: sum of 2 quarters · filed 2026-03-17 | $472.00K derived: sum of 3 quarters · filed 2026-03-17 | $126.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $717.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $956.00K derived: sum of 2 quarters · filed 2025-11-12 | $610.00K 10-Q · filed 2025-11-12 | $303.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$107.00K 10-Q · filed 2025-08-12 | -$414.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$346.00K 10-Q · filed 2025-05-13 | -$653.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $666.00K 10-K · filed 2025-03-25 | ||
| 2023-09-30 | $973.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |